Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says

Executive Summary

BioMarin’s focus on rare diseases and gene therapies and expected financial growth make it a logical acquisition target for almost any large pharma, though Biogen, Amgen and Regeneron also offer a beneficial fit for many.


Related Content

Celgene/Bristol: Happy Union Or Runaway Bride?
Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea
Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors
Pfizer: Time To Face The Lyrica Pain
Bristol/Celgene Made Perfect Sense, But Doesn’t Promise Big M&A Year, EY Says
Bristol/Celgene A Record-Setting Merger, If It Happens
Why The M&A Boom Many Expected In 2018 Didn’t Happen
Pfizer On Reorganizing, M&A And Investing In Internal R&D
BioMarin Gets Second PKU Approval, Anticipates Slow Ramp-Up For Palynziq
BioMarin Drops Pompe Drug In Hunt For Profitability


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts